Best Life Sciences Companies in Arizona, United States
The 256 best Life Sciences companies in Arizona, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Accelerate Diagnostics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Arizona
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Accelerate Diagnostics Developer of diagnostic devices and test kits for the antibiotic resistant infections | $366M | 63 mo ago | Public | 197 | — | Top 50M | 90 patents Lens-free holographic imaging for label‑free cellular/microbial detection and susceptibility testing | — |
| 2 | Dermavant Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases | $160M | 60 mo ago | Acquired | 73 | Todd Zavodnick CEO | Top 10M | — | — |
| 3 | Align Technology Developer of invisalign clear aligners and other dental products | $105M | 99 mo ago | Public | 1,051 | Joe Hogan CEO | Top 1M | 4,569 patents Digital orthodontic devices, 3D‑printed aligners, and imaging software for tooth modeling and treatment planning. | 1 launch · 1 award |
| 4 | Zounds Hearing Online slot site offering deposit options with potential jackpot wins | $103M | 144 mo ago | Series B | 43 | — | Top 50M | 13 patents Advanced hearing aid tip designs, calibration methods, and communication/control technologies. | — |
| 5 | GT Medical Technologies Provider of medical devices for radiation therapy for bran tumor treatment | $79M | 17 mo ago | Series C | 29 | Theresa Thomas Co-Founder | Top 50M | 547 patents Patents concentrated in health & consumer products | — |
| 6 | MTM Laboratories In vitro diagnostics with a focus on early detection and diagnosis of cervical cancer | $76M | 187 mo ago | Acquired | — | Peter Pack Founder & CEO | — | — | — |
| 7 | OncoMyx Therapeutics Provider of oncolytic virus-based immunotherapeutics | $75M | 54 mo ago | Deadpooled | 17 | — | — | — | — |
| 8 | Breakthru Medicine Developer of cancer therapeutics designed to address unmet clinical needs | $60M | 4 mo ago | Series A | — | Brian Barnett Co-Founder | Top 50M | — | — |
| 9 | HTG Molecular Diagnostics Developer of diagnostics and targeted therapeutics across a variety of disease areas | $47M | 71 mo ago | Public | 47 | — | Top 5M | 94 patents Molecular diagnostics for cancer via epitranscriptomic biomarkers and targeted sequencing | — |
| 10 | Cayenne Medical Pioneering sports medicine solutions, optimizing patient care through innovation and integration | $46M | 148 mo ago | Acquired | 54 | — | — | 221 patents Nanofiber-based soft tissue repair systems and suture anchor technologies for orthopedic surgery | — |
| 11 | Ultherapy Non-invasive skin lifting and tightening treatments using ultrasound technology | $40M | 184 mo ago | Acquired | 104 | — | Top 1M | — | — |
| 12 | Dot Compliance AI-powered electronic quality management system for life science companies | $33M | 26 mo ago | Series B | 134 | Doron Sitbon Founder & CEO | Top 5M | — | 1 launch |
| 13 | CyMedica Ortho At-home muscle strengthening therapy for lasting knee pain relief | $33M | 76 mo ago | Series A | 14 | Struan Coleman Co-Founder | — | — | — |
| 14 | Creative Medical Technologies Stem-cell based therapeutics for male and female reproductive health | $19M | 49 mo ago | Public | 4 | — | Top 50M | — | — |
| 15 | SenesTech Provider of fertility management solutions for pest control | $17M | 64 mo ago | Public | 25 25 → 45 (+80%) | — | Top 5M | 49 patents Rodent and wildlife fertility control via bait stations and contraceptive delivery systems | — |
| 16 | NeoLight Provider of LED phototherapy to treat neonatal jaundice | $17M | 67 mo ago | Series B | 55 | — | Top 10M | 32 patents Ophthalmic phototherapy devices and wide-field retinal imaging systems | — |
| 17 | Cancer Prevention Pharmaceuticals Your trusted source for health education, tips, and guidance | $16M | 64 mo ago | Acquired | 14 | Frank Meyskens Co-Founder | — | — | — |
| 18 | Vomaris Innovations Wound healing using bio mimicking technology | $16M | 90 mo ago | Series B | 18 | Michael Nagel President & CEO | Top 50M | 152 patents Advanced wound care, fixation, and bioelectric therapeutic devices for musculoskeletal health | — |
| 19 | CND Life Sciences Provider of a neurological disease diagnostic tool for providers | $16M | 13 mo ago | Series A | 22 | Roy Freeman Co-Founder | Top 5M | — | — |
| 20 | Calimmune Developer of autologous cell therapies to enhance immune response for infectious diseases | $16M | 132 mo ago | Acquired | 23 | — | — | 72 patents Gene therapy vector platforms for AAV/lentiviral delivery targeting hemoglobinopathies and HIV. | — |
| 21 | ExsoMed Orthopedic implants for hand and wrist | $16M | 61 mo ago | Series A | 29 | — | — | 79 patents Small bone orthopedic fixation devices and wrist fusion implants | — |
| 22 | Pre Nexus Health Natural Prebiotic Ingredients for the Next Generation in Healthy Nutrition | $15M | 58 mo ago | Series B | 17 | Sandra Saville Co-Founder | — | — | — |
| 23 | Anuncia Medical Developer of a neuro therapeutic device for cerebrospinal fluid (CSF) management | $15M | 21 mo ago | Series A | 19 | Elsa Abruzzo CEO & President | — | — | — |
| 24 | Procellera Wound Dressing based on Microcurrent technology. | $14M | 120 mo ago | Series A | — | Michael Nagel CEO & President | — | — | — |
| 25 | Radiance Therapeutics Developer of beta ophthalmic applicator for glaucoma | $14M | 52 mo ago | Series B | 6 | — | — | — | — |
| 26 | Regenesis Provider of at-home non-drug pain relief solutions for patients | $13M | 180 mo ago | Series C | 57 57 → 120 (+111%) | Tom Eisiminger CEO | Top 50M | 10 patents Patents concentrated in chemistry & materials | 1 award |
| 27 | Luceome Biotechnologies Develop assay technology for the identification of drugs against kinases | $13M | 50 mo ago | Funding Raised | 9 | — | — | — | — |
| 28 | Valley Fever Solutions Developing innovative antifungal solutions to conquer Valley Fever and fungal diseases | $12M | 144 mo ago | Funding Raised | — | David Larwood Co-Founder & CEO | — | — | — |
| 29 | PathogenDX Provider of DNA-based pathogen testing kits | $12M | 70 mo ago | Series B | 31 31 → 26 (-16%) | Milan Patel CEO and Co-Founder | Top 50M | 69 patents Nucleic acid amplification and multiplex detection of RNA pathogens | 1 launch |
| 30 | Paradigm Dx Eradicating cancer through prevention, early detection, and personalized therapy guidance | $11M | 85 mo ago | Acquired | 23 | — | — | 29 patents Patents concentrated in electrical & electronics | — |
| 31 | Biosensing Instrument Surface analytical instruments for life sciences and materials applications | $11M | 14 mo ago | Funding Raised | 15 | Tianwei Jing President and Co-founder | Top 50M | — | 1 launch |
| 32 | DMetrix Developer of microscopic-imaging instrumentation for telepathology and life science applications | $10M | 155 mo ago | Funding Raised | — | Artur Olszak Founder & CEO | — | 39 patents Advanced optical metrology for non‑spherical surface interferometry and focus prediction | — |
| 33 | Nevoa Automating hospital disinfection with innovative fogging technology and solutions | $10M | 17 mo ago | Series B | 12 | Mike Hudson CEO | — | 2 patents Chlorine-based antiviral disinfection and catalytic hydrocarbon oxidation technologies. | — |
| 34 | EPIC Research & Diagnostics Digital skin response or electrodermal response (EDR) measurement systems | $8M | 118 mo ago | Seed | 13 | Nancy R. Rizzo Founder and CEO | — | — | — |
| 35 | Reglagene Developer of drugs for treating cancer | $7M | 25 mo ago | Series A | 12 | — | — | 12 patents Small‑molecule tubulin‑targeted therapeutics for cancer and related health conditions | — |
| 36 | Salutaris Medical Devices Saving vision with precision beta radiotherapy for age-related macular degeneration | $6M | 100 mo ago | Series A | 4 | — | — | — | — |
| 37 | Asantae Manufacturer and marketer of condition-specific health supplement products | $6M | 124 mo ago | Acquired | — | Doug Ridley CEO & President | — | — | — |
| 38 | Planatome Developer of surgical scalpels for hospital & doctors use | $6M | 31 mo ago | Series A | — | Tim Tobin CEO | — | 6 patents Optimized surface‑textured surgical cutting instruments for enhanced precision | — |
| 39 | BMSEED Integrated biomechanics, imaging, and electrophysiology tools for in vitro research | $5M | 44 mo ago | Funding Raised | 4 | Oliver Graudejus Founder & CEO | — | 4 patents Soft, stretchable microelectrode arrays for peripheral nerve bioelectronic interfaces | — |
| 40 | Med-Surgical Provider of an image-guided surgical system for surgical procedures | $4M | 29 mo ago | Series A | — | Rory Randall Co-CEO | — | — | — |
| 41 | CATS Developer of intraocular pressure monitoring device | $3M | 15 mo ago | Funding Raised | 3 | — | — | — | — |
| 42 | ProNeurogen Developer of therapeutics to treat vascular dementia and neuropathic pain | $3M | 33 mo ago | Funding Raised | — | Meredith Hay Founder & CEO | — | 8 patents Peptide therapeutics targeting amyloid imaging and sustained-release angiotensin‑(1‑7) formulations | — |
| 43 | QScint Provider of real-time alpha- and beta-particle imaging systems | $2M | 10 mo ago | Funding Raised | — | Brian Miller Founder | — | — | — |
| 44 | Fibronox Developer of novel treatments for fibrotic diseases | $1M | 24 mo ago | Funding Raised | — | Louise Hecker Founder & CSO | — | — | — |
| 45 | NuvOx Therapeutics Developer of an oxygen therapeutic drug designed to reverse tissue hypoxia | $1M | 14 mo ago | Funding Raised | — | Jennifer Johnson Co-Founder & Chief Scientific Officer | Top 50M | — | — |
| 46 | Binary Genomics Developer of a pan-cancer detection blood test | $1M | 21 mo ago | Funding Raised | — | Mitesh Borad Co-Founder | — | — | — |
| 47 | Emagine Solutions Technology Provider of pregnancy management app and device for women and healthcare providers | $1M | 34 mo ago | Funding Raised | 5 | — | — | — | — |
| 48 | LEAH Labs Developer of gene editing tools for dogs to fight against cancer | $1M | 32 mo ago | Seed | 7 | — | — | — | — |
| 49 | Delta Development Team Manufacturer of ruggedized thermal systems | $960K | 10 mo ago | Series A | 19 | William Barg Co-Founder | Top 1M | — | 1 launch |
| 50 | Biomotum Provides robotic assistive devices for children and adults with movement disorders | $660K | 10 mo ago | Seed | 7 | Joseph Lerner Co-Founder | — | — | — |
Top 12 Life Sciences companies in Arizona
#1
Series A · Glendale, Arizona · founded 2024$60Mraised▾
Developer of cancer therapeutics designed to address unmet clinical needs. The company advances a portfolio of therapeutics through independent programs and platform technologies. It focuses on oncology drug development and capital-efficient strategies. The company aims to deliver therapies while creating value for stakeholders.
- Jan 2026Series A$60M
- Seed—
#2
Series C · Tempe, Arizona · founded 2017 · 29 employees$78.6Mraised▾
Provider of medical devices for radiation therapy for bran tumor treatment. It offers GammaTile Therapy is surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors. The technology uses a combination of a collagen matrix with brachytherapy seeds.
- Dec 2024Series C$53.3M
- Sep 2024Venture Debt$35M
- Mar 2023Series C$45M
- Nov 2020Series B$16M
#3
Series A · Phoenix, Arizona · founded 2017 · 22 employees$16Mraised▾
Provider of a neurological disease diagnostic tool for providers. The company has developed a diagnostic kit called Syn-One Test which assists in the diagnosis of synucleinopathy in patients. The kit is a skin biopsy tool that has the ability to detect and visualize abnormal skin cell conditions based on pathological evidence.
- May 2025Series A$13.5M
- Apr 2025Grant (prize money)$2.4M
- Feb 2025Series A$8.6M
- Mar 2024Seed$2M
#4
Funding Raised · Tempe, Arizona · founded 2015 · 15 employees$10.6Mraised▾
Biosensing Instrument is a precision scientific instruments company focused on developing molecular analytical instruments based on Surface Plasmon Resonance technology. The company's proprietary Bi-DirectFlow SPR technology allows combining precise sample delivery at small volume with a noise and drift cancellation technique to meet the requirements for a diverse set of applications in life science, electrochemistry, chemical vapor research, and environmental safety.
- Apr 2025Grant (prize money)$349.6K
- Sep 2024Grant (prize money)$295.6K
- Aug 2021Grant (prize money)$2.2M
- May 2021Grant (prize money)$1.7M
#5
Funding Raised · Tucson, Arizona · founded 2019$2.4Mraised▾
Provider of real-time alpha- and beta-particle imaging systems. These systems are used for digital autoradiography, radiopharmaceutical development, targeted alpha therapy, radioactivity quality assurance, and geochronology. The systems are lightweight and easy to install, facilitating various research and industrial applications. They enable visualization and capture of digital images showing the spatial distribution of alpha- and beta-emitting radionuclides in diverse samples. The technology also supports applications in screening for alpha-emitting poisons.
- Aug 2025Grant (prize money)$1.6M
- Sep 2024Grant (prize money)$811.5K
#6
Series B · Scottsdale, Arizona · founded 2009 · 12 employees$10.3Mraised▾
Automating hospital disinfection with innovative fogging technology and solutions, dedicated to revolutionizing healthcare disinfection practices. They offer technology-based solutions that automate disinfection and cleaning, reducing hospital-acquired infections (HAIs) and improving patient safety. Their product line includes whole-room fogging technology, handheld foggers for between-case disinfection, and hypochlorous acid solutions. They aim to transform manual disinfection processes into highly effective, automated protocols, providing superior disinfection at a reduced cost. Their solutions enhance patient outcomes, lower healthcare costs, and increase hospital staff efficiency. They provide innovative solutions to a persistent problem in the healthcare industry, focusing on improving the quality of care and reducing the risk of infections. They offer a comprehensive approach to hospital disinfection, utilizing advanced technology and effective disinfection protocols.
- Dec 2024Series B$5.9M
- Nov 2019Series A$2.9M
- Nov 2018Seed$1.5M
#7
Series A · Scottsdale, Arizona · founded 2018 · 19 employees$14.6Mraised▾
Developer of a neuro therapeutic device for cerebrospinal fluid (CSF) management. The company offers "ReFlow" an implanted shunt system to restore CSF flow for the diagnosis, treatment, or follow-up of patients with ventricular catheter occlusions.
- Aug 2024Series A$13.9M
- Aug 2022Seed$3.4M
- Dec 2021Seed$427.5K
#8
Funding Raised · Tucson, Arizona · founded 2018 · 3 employees$3.4Mraised▾
CATS Tonometer has developed a device for monitoring the intraocular pressure. The products developed is a FDA cleared, patented device called Prism for measuring the IOP used for diagnosing and treating glaucoma and other ocular related diseases.
- Mar 2025Grant (prize money)$1.1M
- Sep 2018Grant (prize money)$1.1M
- Jun 2018Grant (prize money)$1.1M
#9
Seed · Flagstaff, Arizona · founded 2019 · 7 employees$660Kraised▾
Biomotum manufactures robotic assistive devices for children and adults with movement disorders. The device has mobility benefits, including improved coordination, reduced energy cost to walk, increased walking speed and improved leg strength.
- Aug 2025Grant (prize money)$263.6K
- Jan 2025Grant (prize money)$1.9M
- Jul 2023Grant (prize money)$274.3K
- Sep 2021Grant (prize money)$1.9M
#10
Series A · Tucson, Arizona · founded 2018 · 19 employees$960Kraised▾
Manufacturer of ruggedized thermal systems
- Aug 2025Grant (prize money)—
- Aug 2025Series A—
- Dec 2024Series A$357.8K
- Sep 2023Series A$960K
#11
Funding Raised · Tucson, Arizona · founded 2008$1.4Mraised▾
Developer of an oxygen therapeutic drug designed to reverse tissue hypoxia. The company focuses on developing a drug that improves oxygen flow from lungs to blood and from blood to tissue. Animal studies have demonstrated therapeutic effects across multiple indications. The company's clinical programs include trials for glioblastoma, stroke, and respiratory distress. The therapeutic drug is currently under clinical investigation and not yet approved for general medical use.
- Apr 2025Grant (prize money)$900.4K
- May 2010Grant (prize money)$204.4K
- Dec 2009Grant (prize money)$303.7K
#12
Series B · Phoenix, Arizona · founded 2016 · 134 employees$33Mraised▾
AI-powered electronic quality management system for life science companies. It enhances the CAPA process by guiding quality teams through establishing and maintaining compliant CAPA procedures. It automates documentation, revision management, and reporting. It helps life sciences companies streamline quality processes, reduce regulatory risks, and bring products to market.
- Apr 2024Series B$17.5M
- Jul 2022Series B$23M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Arizona is moving
A read on the academic research around Biotechnology in Arizona — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 75 papers.
University of Arizona, Mayo Clinic, and ASU lead Arizona's biotechnology research, focusing on RNA interference, algal biofuels, and microbial engineering, with a cautiously optimistic tone.
- University of Arizona29
- Mayo Clinic in Arizona23
- Arizona State University20
- University of Arizona Cancer Center3
- Arizona Oncology1
- Gene knockdown4
- Gene4
- Genome4
- Transcription factor2
- Gene expression2
- Immunofluorescence2
- Biofilm2
- Gene2
- Gene expression2
- Cell culture2
- Agriculture2
- Biomanufacturing1
- Escherichia coli1
- Extracellular1
- Melanin1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.